Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Building 10, CRC, Room 1-3330, 10 Center Drive, MSC1103, Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2012 Mar;97(3):E357-66. doi: 10.1210/jc.2011-1179. Epub 2011 Dec 14.
Mutations in the subunits B, C, and D of succinate dehydrogenase (SDH) mitochondrial complex II have been associated with the development of paragangliomas (PGL), gastrointestinal stromal tumors, papillary thyroid and renal carcinoma (SDHB), and testicular seminoma (SDHD).
Our aim was to examine the possible causative link between SDHD inactivation and somatotropinoma.
A 37-yr-old male presented with acromegaly and hypertension. Other family members were found with PGL. Elevated plasma and urinary levels of catecholamines led to the identification of multiple PGL in the proband in the neck, thorax, and abdomen. Adrenalectomy was performed for bilateral pheochromocytomas (PHEO). A GH-secreting macroadenoma was also found and partially removed via transsphenoidal surgery (TTS). Genetic analysis revealed a novel SDHD mutation (c.298_301delACTC), leading to a frame shift and a premature stop codon at position 133 of the protein. Loss of heterozygosity for the SDHD genetic locus was shown in the GH-secreting adenoma. Down-regulation of SDHD protein in the GH-secreting adenoma by immunoblotting and immunohistochemistry was found. A literature search identified other cases of multiple PGL and/or PHEO in association with pituitary tumors.
We describe the first kindred with a germline SDHD pathogenic mutation, inherited PGL, and acromegaly due to a GH-producing pituitary adenoma. SDHD loss of heterozygosity, down-regulation of protein in the GH-secreting adenoma, and decreased SDH enzymatic activity supports SDHD's involvement in the pituitary tumor formation in this patient. Older cases of multiple PGL and PHEO and pituitary tumors in the literature support a possible association between SDH defects and pituitary tumorigenesis.
琥珀酸脱氢酶(SDH)线粒体复合物 II 的亚基 B、C 和 D 的突变与副神经节瘤(PGL)、胃肠道间质瘤、甲状腺乳头状癌和肾细胞癌(SDHB)以及睾丸精原细胞瘤(SDHD)的发生有关。
我们旨在研究 SDHD 失活与生长激素腺瘤之间可能存在的因果关系。
一名 37 岁男性因肢端肥大症和高血压就诊。其他家族成员患有 PGL。检测到儿茶酚胺的血浆和尿液水平升高,导致在该患者的颈部、胸部和腹部发现多个 PGL。双侧嗜铬细胞瘤(PHEO)行肾上腺切除术。还发现了一个生长激素分泌的大腺瘤,并通过经蝶窦手术(TTS)部分切除。基因分析显示一个新的 SDHD 突变(c.298_301delACTC),导致蛋白 133 位的移码和提前终止密码子。在生长激素分泌腺瘤中显示 SDHD 遗传基因座的杂合性丢失。免疫印迹和免疫组化显示生长激素分泌腺瘤中 SDHD 蛋白表达下调。文献检索发现其他多个 PGL 和/或 PHEO 与垂体肿瘤相关的病例。
我们描述了第一个家族性 SDHD 致病性突变,遗传性 PGL 和生长激素腺瘤导致的肢端肥大症。SDHD 杂合性丢失、生长激素分泌腺瘤中蛋白表达下调以及 SDH 酶活性降低支持 SDHD 参与该患者垂体肿瘤的形成。文献中更早期的多个 PGL 和 PHEO 以及垂体肿瘤病例支持 SDH 缺陷与垂体肿瘤发生之间可能存在关联。